ANALYSIS OF NON-INVASIVE LIVER BIOMARKERS IN A PHASE I I TRIAL OF THE GLUCAGON AND GLP-1 RECEPTOR DUAL AGONIST SURVODUTIDE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND FIBROSIS

被引：0

作者：

Noureddin, Mazen ^{[1
]}

Schoelch, Corinna ^{[2
]}

Bugianesi, Elisabetta ^{[3
]}

Alkhouri, Naim ^{[4
,5
]}

Fraessdorf, Mandy ^{[6
]}

Schattenberg, Joern ^{[7
]}

Newsome, Philip ^{[8
]}

Anstee, Quentin ^{[9
]}

Neff, Guy ^{[10
]}

Coxson, Harvey ^{[2
]}

Lawitz, Eric ^{[4
]}

Ratziu, Vlad ^{[11
]}

Nakajima, Atsushi ^{[12
]}

Hosseini-Tabatabaei, Azadeh ^{[13
]}

Sanyal, Arun ^{[14
]}

Younes, Ramy ^{[6
]}

机构：

[1] Houston Methodist Hosp, Houston, TX 77030 USA

[2] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[3] Univ Turin, Div Gastroenterol, Dept Med Sci, Turin, Italy

[4] Univ Texas Hlth San Antonio, Texas Liver Inst, San Antonio, TX USA

[5] Arizona Liver Hlth, Phoenix, AZ USA

[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[7] Saarland Univ, Dept Internal Med 2, Med Ctr, Homburg, Germany

[8] Univ Hosp Birmingham, Natl Inst Hlth Res, Biomed Res Ctr, Birmingham, W Midlands, England

[9] Newcastle Univ, Fac Med Sci, Newcastle Upon Tyne, Tyne & Wear, England

[10] Covenant Metab Specialists LLC, Sarasota, FL USA

[11] Sorbonne Univ, Inst Cardiometab & Nutr, Hop Pitie Salpetriere, Paris, France

[12] Yokohama City Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Yokohama, Kanagawa, Japan

[13] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA

[14] Virginia Commonwealth Univ, Richmond, VA 23284 USA

来源：

HEPATOLOGY | 2024年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

2647

引用

页码：S2005 / S2006

页数：2

共 34 条

[21] Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Matthias Blüher
Julio Rosenstock
Josef Hoefler
Raymond Manuel
Anita M. Hennige
Diabetologia, 2024, 67 : 470 - 482
[22] ASSOCIATION OF GLUCAGON-LIKE PEPTIDASE 1 RECEPTOR AGONIST WITH LIVER AND NON-LIVER COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Nguyen, Mindie
Mao, Xianhua
Zhang, Xinrong
Lai, Rongtao
Cheung, Ka-Shing
Yuen, Man-Fung
Cheung, Ramsey
Seto, Wai-Kay
HEPATOLOGY, 2024, 80 : S884 - S884
[23] Correction to: Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Matthias Blüher
Julio Rosenstock
Josef Hoefler
Raymond Manuel
Anita M. Hennige
Diabetologia, 2024, 67 : 758 - 758
[24] Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Blueher, Matthias
Rosenstock, Julio
Hoefler, Josef
Manuel, Raymond
Hennige, Anita M.
DIABETOLOGIA, 2024, 67 (03) : 470 - 482
[25] Phase 2, randomised, placebo-controlled trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in subjects with overweight or obesity: a 24-week interim analysis
Aronne, L.
Harris, M. S.
Roberts, M. S.
Suschak, J.
Tomah, S.
He, L.
Yang, J.
Frias, J. P.
Browne, S. K.
DIABETOLOGIA, 2023, 66 (SUPPL 1) : S33 - S34
[26] Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis
Akhverdyan, Nazar
Wieland, Amanda
Sullivan, Shelby
Lindsay, Mark
Swartwood, Sheila
Arndt, Gretchen
Kaizer, Laura Katherine
Jensen, Thomas
METABOLIC SYNDROME AND RELATED DISORDERS, 2024, 22 (08) : 608 - 618
[27] Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial (vol 67, pg 470, 2024)
Blueher, Matthias
Rosenstock, Julio
Hoefler, Josef
Manuel, Raymond
Hennige, Anita M.
DIABETOLOGIA, 2024, 67 (04) : 758 - 758
[28] Phase 3 randomised, placebo-controlled ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-invasive tests
George, Jacob
Newsome, Philip N.
Bugianesi, Elisabetta
Ratziu, Vlad
Rinella, Mary E.
Roden, Michael
Engebretsen, Kristiane A.
Kliers, Iris
Ostergaard, Laura
Vanni, Denise
Zacho, Jeppe
Sanyal, Arun J.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 72 - 73
[29] Phase 3 randomised, placebo-controlled ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-invasive tests
Newsome, Philip N.
Bugianesi, Elisabetta
Ratziu, Vlad
Rinella, Mary E.
Roden, Michael
Engebretsen, Kristiane A.
Kliers, Iris
Ostergaard, Laura
Vanni, Denise
Zacho, Jeppe
Sanyal, Arun J.
JOURNAL OF HEPATOLOGY, 2024, 80 : S606 - S607
[30] Effects of icosabutate, a dual free fatty acid receptor-1 and-4 agonist, on elevated non-invasive markers of liver injury, fibrosis and glycemic control in type 2 diabetic MASH patients and F1-F3 fibrosis
Alkhouri, Naim
Fraser, David A.
Steineger, Hilde
Noureddin, Mazen
Anstee, Quentin M.
Harrison, Stephen A.
JOURNAL OF HEPATOLOGY, 2024, 80 : S603 - S604

← 1 2 3 4 →